 Brian Kavanagh
Concepts (624)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 81 | 2023 | 299 | 12.700 |
Why?
| | Radiation Oncology | 28 | 2022 | 75 | 7.000 |
Why?
| | Lung Neoplasms | 59 | 2023 | 2177 | 4.230 |
Why?
| | Prostatic Neoplasms | 29 | 2020 | 921 | 3.630 |
Why?
| | Brain Neoplasms | 34 | 2023 | 979 | 3.410 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 28 | 2023 | 961 | 2.830 |
Why?
| | Radiotherapy | 17 | 2016 | 176 | 2.660 |
Why?
| | Liver Neoplasms | 21 | 2019 | 506 | 2.630 |
Why?
| | Neoplasms | 28 | 2021 | 2097 | 2.370 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 30 | 2023 | 117 | 2.150 |
Why?
| | Radiotherapy Dosage | 44 | 2023 | 244 | 2.040 |
Why?
| | Radiotherapy, Conformal | 17 | 2017 | 68 | 1.990 |
Why?
| | Radiation Injuries | 16 | 2018 | 128 | 1.920 |
Why?
| | Radiotherapy, Intensity-Modulated | 16 | 2019 | 124 | 1.910 |
Why?
| | Glioblastoma | 12 | 2016 | 253 | 1.890 |
Why?
| | Small Cell Lung Carcinoma | 6 | 2023 | 77 | 1.650 |
Why?
| | Four-Dimensional Computed Tomography | 7 | 2021 | 25 | 1.510 |
Why?
| | Cranial Irradiation | 7 | 2020 | 66 | 1.500 |
Why?
| | Cone-Beam Computed Tomography | 9 | 2023 | 25 | 1.390 |
Why?
| | Brachytherapy | 14 | 2016 | 103 | 1.380 |
Why?
| | Dacarbazine | 9 | 2016 | 99 | 1.300 |
Why?
| | Pulmonary Ventilation | 5 | 2021 | 72 | 1.200 |
Why?
| | Humans | 216 | 2023 | 114624 | 1.190 |
Why?
| | Aged | 97 | 2023 | 19061 | 1.190 |
Why?
| | Chemoradiotherapy | 8 | 2020 | 188 | 1.140 |
Why?
| | Antineoplastic Agents, Alkylating | 6 | 2016 | 68 | 1.130 |
Why?
| | Societies, Medical | 9 | 2021 | 663 | 1.110 |
Why?
| | Radiotherapy, Adjuvant | 8 | 2015 | 182 | 1.090 |
Why?
| | Middle Aged | 100 | 2023 | 26719 | 1.020 |
Why?
| | Aged, 80 and over | 52 | 2020 | 6344 | 0.950 |
Why?
| | Uterine Cervical Neoplasms | 9 | 2016 | 216 | 0.910 |
Why?
| | SEER Program | 10 | 2018 | 196 | 0.910 |
Why?
| | Neoplasm Metastasis | 10 | 2020 | 522 | 0.860 |
Why?
| | Neoplasm Recurrence, Local | 14 | 2014 | 858 | 0.860 |
Why?
| | Male | 109 | 2023 | 55555 | 0.840 |
Why?
| | Radiation Oncologists | 2 | 2022 | 4 | 0.840 |
Why?
| | Radiation Pneumonitis | 6 | 2021 | 24 | 0.810 |
Why?
| | Neoplasm Staging | 24 | 2018 | 1167 | 0.800 |
Why?
| | Radiometry | 10 | 2022 | 42 | 0.800 |
Why?
| | Databases, Factual | 10 | 2017 | 1124 | 0.800 |
Why?
| | Internship and Residency | 5 | 2022 | 926 | 0.790 |
Why?
| | Dose-Response Relationship, Radiation | 20 | 2021 | 127 | 0.770 |
Why?
| | Registries | 5 | 2018 | 1767 | 0.770 |
Why?
| | Whole-Body Irradiation | 4 | 2020 | 73 | 0.760 |
Why?
| | Neoplasm Grading | 6 | 2016 | 242 | 0.750 |
Why?
| | Social Media | 2 | 2020 | 131 | 0.750 |
Why?
| | Liver | 9 | 2018 | 1634 | 0.730 |
Why?
| | United States | 31 | 2022 | 12176 | 0.730 |
Why?
| | Medicine | 2 | 2021 | 102 | 0.710 |
Why?
| | Videoconferencing | 1 | 2020 | 57 | 0.690 |
Why?
| | Travel | 1 | 2020 | 121 | 0.670 |
Why?
| | Carcinoma, Squamous Cell | 8 | 2007 | 577 | 0.660 |
Why?
| | Scattering, Radiation | 5 | 2022 | 92 | 0.660 |
Why?
| | Radiation | 1 | 2019 | 24 | 0.650 |
Why?
| | Female | 97 | 2023 | 59466 | 0.650 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2009 | 140 | 0.650 |
Why?
| | Respiratory Function Tests | 3 | 2023 | 522 | 0.640 |
Why?
| | Models, Economic | 1 | 2019 | 48 | 0.640 |
Why?
| | Carcinoma, Renal Cell | 5 | 2015 | 168 | 0.640 |
Why?
| | Breast Neoplasms | 11 | 2022 | 1862 | 0.640 |
Why?
| | Combined Modality Therapy | 24 | 2019 | 1121 | 0.630 |
Why?
| | Treatment Outcome | 32 | 2023 | 9084 | 0.630 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2019 | 88 | 0.620 |
Why?
| | Astrocytoma | 4 | 2014 | 108 | 0.620 |
Why?
| | Kidney Neoplasms | 6 | 2015 | 327 | 0.620 |
Why?
| | Adult | 68 | 2023 | 30528 | 0.610 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 152 | 0.600 |
Why?
| | Faculty, Medical | 1 | 2020 | 228 | 0.600 |
Why?
| | Lung | 10 | 2023 | 3558 | 0.590 |
Why?
| | Stereotaxic Techniques | 3 | 2006 | 29 | 0.580 |
Why?
| | Antineoplastic Agents | 13 | 2023 | 1879 | 0.560 |
Why?
| | Prostate-Specific Antigen | 8 | 2016 | 151 | 0.560 |
Why?
| | Neoplasms, Second Primary | 2 | 2008 | 92 | 0.550 |
Why?
| | Preoperative Care | 1 | 2018 | 319 | 0.540 |
Why?
| | Quality of Life | 6 | 2021 | 2353 | 0.540 |
Why?
| | Radiotherapy, Computer-Assisted | 6 | 2015 | 12 | 0.520 |
Why?
| | Insurance Coverage | 4 | 2019 | 200 | 0.510 |
Why?
| | Models, Biological | 8 | 2018 | 1620 | 0.510 |
Why?
| | Organs at Risk | 5 | 2021 | 30 | 0.500 |
Why?
| | Androgen Antagonists | 6 | 2020 | 69 | 0.500 |
Why?
| | Prospective Studies | 22 | 2023 | 6217 | 0.500 |
Why?
| | Disease-Free Survival | 12 | 2019 | 620 | 0.480 |
Why?
| | Magnetic Resonance Imaging | 9 | 2023 | 3039 | 0.480 |
Why?
| | Oligodendroglioma | 1 | 2014 | 15 | 0.480 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 90 | 0.470 |
Why?
| | Radiation Tolerance | 6 | 2015 | 92 | 0.460 |
Why?
| | Immunologic Factors | 1 | 2016 | 220 | 0.460 |
Why?
| | Clinical Trials as Topic | 9 | 2017 | 931 | 0.460 |
Why?
| | Health Physics | 2 | 2016 | 4 | 0.460 |
Why?
| | Checklist | 1 | 2015 | 83 | 0.460 |
Why?
| | Perfusion Imaging | 1 | 2014 | 51 | 0.450 |
Why?
| | Beauty | 1 | 2013 | 11 | 0.450 |
Why?
| | Protein Kinase Inhibitors | 6 | 2019 | 785 | 0.450 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2019 | 1355 | 0.440 |
Why?
| | Phantoms, Imaging | 5 | 2023 | 122 | 0.440 |
Why?
| | Retrospective Studies | 34 | 2023 | 12542 | 0.440 |
Why?
| | Spiral Cone-Beam Computed Tomography | 2 | 2023 | 3 | 0.430 |
Why?
| | Artifacts | 4 | 2019 | 113 | 0.430 |
Why?
| | ErbB Receptors | 10 | 2023 | 554 | 0.430 |
Why?
| | Medicare | 4 | 2021 | 665 | 0.430 |
Why?
| | Oxygen | 5 | 2016 | 854 | 0.420 |
Why?
| | Credentialing | 1 | 2012 | 12 | 0.420 |
Why?
| | Liver Regeneration | 2 | 2012 | 29 | 0.420 |
Why?
| | Kaplan-Meier Estimate | 11 | 2019 | 811 | 0.410 |
Why?
| | Proton Therapy | 2 | 2015 | 10 | 0.410 |
Why?
| | Survival Analysis | 11 | 2020 | 1211 | 0.400 |
Why?
| | Follow-Up Studies | 18 | 2019 | 4411 | 0.400 |
Why?
| | Antibodies | 2 | 2018 | 371 | 0.390 |
Why?
| | Hemoglobin A | 2 | 2002 | 21 | 0.390 |
Why?
| | Rectum | 4 | 2014 | 153 | 0.380 |
Why?
| | Survival Rate | 13 | 2019 | 1644 | 0.380 |
Why?
| | Consensus | 4 | 2022 | 537 | 0.380 |
Why?
| | Lymph Nodes | 1 | 2014 | 419 | 0.380 |
Why?
| | Carcinoma | 2 | 2006 | 198 | 0.380 |
Why?
| | Relative Biological Effectiveness | 2 | 2008 | 3 | 0.370 |
Why?
| | Erlotinib Hydrochloride | 4 | 2019 | 64 | 0.350 |
Why?
| | Prognosis | 15 | 2020 | 3328 | 0.350 |
Why?
| | Radiotherapy, High-Energy | 2 | 2008 | 12 | 0.350 |
Why?
| | Comparative Effectiveness Research | 1 | 2011 | 130 | 0.350 |
Why?
| | Skin Neoplasms | 2 | 2015 | 756 | 0.350 |
Why?
| | Antigens, Neoplasm | 3 | 2009 | 221 | 0.350 |
Why?
| | Neoplastic Stem Cells | 1 | 2013 | 329 | 0.340 |
Why?
| | Proportional Hazards Models | 9 | 2019 | 1075 | 0.340 |
Why?
| | Stomach | 1 | 2010 | 102 | 0.340 |
Why?
| | Positron-Emission Tomography | 6 | 2019 | 259 | 0.330 |
Why?
| | Career Choice | 2 | 2021 | 177 | 0.330 |
Why?
| | Antigens, CD | 2 | 2009 | 442 | 0.320 |
Why?
| | Intestine, Small | 1 | 2010 | 122 | 0.320 |
Why?
| | Cell Hypoxia | 3 | 2002 | 220 | 0.320 |
Why?
| | Risk Assessment | 4 | 2015 | 2967 | 0.310 |
Why?
| | Head and Neck Neoplasms | 3 | 2008 | 427 | 0.310 |
Why?
| | Respiratory Mechanics | 1 | 2008 | 56 | 0.310 |
Why?
| | Receptor Protein-Tyrosine Kinases | 4 | 2015 | 226 | 0.300 |
Why?
| | Medical Oncology | 3 | 2020 | 229 | 0.300 |
Why?
| | Quinazolines | 6 | 2014 | 240 | 0.300 |
Why?
| | Vision, Ocular | 1 | 2008 | 30 | 0.300 |
Why?
| | Radiation Protection | 2 | 2009 | 34 | 0.290 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2008 | 53 | 0.290 |
Why?
| | Orbit | 1 | 2008 | 59 | 0.290 |
Why?
| | Pyrazoles | 4 | 2021 | 362 | 0.290 |
Why?
| | Colorectal Neoplasms | 4 | 2017 | 615 | 0.280 |
Why?
| | Pyridines | 4 | 2021 | 425 | 0.280 |
Why?
| | Spinal Neoplasms | 2 | 2007 | 28 | 0.280 |
Why?
| | Bone Neoplasms | 4 | 2019 | 194 | 0.280 |
Why?
| | Prostatectomy | 3 | 2014 | 98 | 0.280 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2007 | 22 | 0.280 |
Why?
| | Linear Models | 2 | 2010 | 768 | 0.280 |
Why?
| | Algorithms | 7 | 2017 | 1466 | 0.270 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2006 | 29 | 0.270 |
Why?
| | Radiation-Sensitizing Agents | 3 | 2001 | 38 | 0.270 |
Why?
| | Melanoma | 3 | 2018 | 619 | 0.270 |
Why?
| | Urologic Diseases | 1 | 2006 | 35 | 0.270 |
Why?
| | Patient Selection | 3 | 2021 | 641 | 0.270 |
Why?
| | Cancer Vaccines | 1 | 2007 | 137 | 0.270 |
Why?
| | Time Factors | 9 | 2021 | 6112 | 0.270 |
Why?
| | Glomus Jugulare Tumor | 1 | 2006 | 5 | 0.270 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2007 | 172 | 0.260 |
Why?
| | Tumor Burden | 9 | 2014 | 259 | 0.260 |
Why?
| | Immunotherapy, Adoptive | 1 | 2007 | 183 | 0.250 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2008 | 339 | 0.250 |
Why?
| | Necrosis | 4 | 2022 | 211 | 0.250 |
Why?
| | Central Nervous System | 3 | 2023 | 235 | 0.250 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2008 | 196 | 0.250 |
Why?
| | Practice Guidelines as Topic | 5 | 2021 | 1394 | 0.250 |
Why?
| | Lymphocyte Activation | 2 | 2009 | 1037 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 11 | 2015 | 2279 | 0.240 |
Why?
| | Insurance, Health | 2 | 2018 | 244 | 0.240 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 338 | 0.240 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2007 | 211 | 0.240 |
Why?
| | CTLA-4 Antigen | 3 | 2018 | 76 | 0.240 |
Why?
| | Coronavirus Infections | 2 | 2020 | 330 | 0.240 |
Why?
| | Data Mining | 2 | 2016 | 100 | 0.240 |
Why?
| | Signal-To-Noise Ratio | 3 | 2019 | 56 | 0.240 |
Why?
| | Particle Accelerators | 3 | 2019 | 9 | 0.230 |
Why?
| | Dendritic Cells | 1 | 2007 | 435 | 0.230 |
Why?
| | Propionates | 2 | 2001 | 34 | 0.230 |
Why?
| | Rectal Neoplasms | 4 | 2008 | 121 | 0.230 |
Why?
| | Chemotherapy, Adjuvant | 7 | 2015 | 332 | 0.220 |
Why?
| | Aniline Compounds | 2 | 2001 | 70 | 0.220 |
Why?
| | Oncogene Addiction | 1 | 2023 | 5 | 0.210 |
Why?
| | Molecular Targeted Therapy | 2 | 2016 | 347 | 0.210 |
Why?
| | Radiopharmaceuticals | 3 | 2014 | 157 | 0.210 |
Why?
| | Inappropriate ADH Syndrome | 2 | 1993 | 7 | 0.210 |
Why?
| | Nasopharyngeal Neoplasms | 2 | 1993 | 13 | 0.210 |
Why?
| | Propensity Score | 4 | 2018 | 224 | 0.210 |
Why?
| | Radiography | 6 | 2014 | 812 | 0.200 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2008 | 959 | 0.200 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2013 | 113 | 0.200 |
Why?
| | Pandemics | 2 | 2020 | 1317 | 0.200 |
Why?
| | Analysis of Variance | 4 | 2016 | 1226 | 0.190 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2023 | 395 | 0.190 |
Why?
| | Pelvis | 3 | 2023 | 90 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2021 | 25 | 0.190 |
Why?
| | Mass Screening | 1 | 2008 | 1004 | 0.190 |
Why?
| | Erythropoietin | 1 | 2001 | 72 | 0.180 |
Why?
| | Lymphatic Metastasis | 3 | 2019 | 275 | 0.180 |
Why?
| | National Cancer Institute (U.S.) | 2 | 2017 | 40 | 0.180 |
Why?
| | Gene Rearrangement | 3 | 2018 | 135 | 0.180 |
Why?
| | Pyrimidines | 2 | 2021 | 376 | 0.180 |
Why?
| | Palatal Neoplasms | 1 | 2000 | 4 | 0.180 |
Why?
| | Anemia | 1 | 2001 | 143 | 0.170 |
Why?
| | Technology, Radiologic | 2 | 2010 | 6 | 0.170 |
Why?
| | Radiographic Image Enhancement | 1 | 2000 | 52 | 0.170 |
Why?
| | Adenocarcinoma | 4 | 2008 | 795 | 0.170 |
Why?
| | Proto-Oncogene Proteins | 2 | 2023 | 608 | 0.170 |
Why?
| | Electromagnetic Phenomena | 1 | 2019 | 22 | 0.170 |
Why?
| | Pelvic Neoplasms | 1 | 1999 | 18 | 0.170 |
Why?
| | Relative Value Scales | 1 | 2019 | 5 | 0.170 |
Why?
| | Suggestion | 1 | 2019 | 5 | 0.170 |
Why?
| | Erythrocyte Transfusion | 1 | 2001 | 189 | 0.170 |
Why?
| | Fluoroscopy | 1 | 2000 | 139 | 0.170 |
Why?
| | Cohort Studies | 4 | 2018 | 4894 | 0.170 |
Why?
| | Thoracic Neoplasms | 3 | 2015 | 32 | 0.170 |
Why?
| | Radiography, Interventional | 1 | 2000 | 104 | 0.170 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2020 | 63 | 0.160 |
Why?
| | Clinical Coding | 1 | 2019 | 19 | 0.160 |
Why?
| | Consolidation Chemotherapy | 1 | 2019 | 9 | 0.160 |
Why?
| | Patient Care Planning | 1 | 2000 | 139 | 0.160 |
Why?
| | Genital Neoplasms, Female | 1 | 2000 | 70 | 0.160 |
Why?
| | Epidermal Growth Factor | 2 | 1998 | 161 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 3 | 2019 | 682 | 0.160 |
Why?
| | Aquaporin 4 | 1 | 2019 | 87 | 0.160 |
Why?
| | Farms | 1 | 2018 | 1 | 0.160 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1998 | 172 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2006 | 1183 | 0.150 |
Why?
| | Policy | 1 | 2019 | 137 | 0.150 |
Why?
| | Karnofsky Performance Status | 3 | 2015 | 36 | 0.150 |
Why?
| | Risk Factors | 7 | 2016 | 8628 | 0.150 |
Why?
| | Organ Size | 3 | 2018 | 434 | 0.150 |
Why?
| | Urinary Bladder | 2 | 2010 | 162 | 0.150 |
Why?
| | Industry | 1 | 2018 | 65 | 0.150 |
Why?
| | Frontal Lobe | 1 | 1998 | 141 | 0.150 |
Why?
| | Health Priorities | 1 | 2017 | 34 | 0.150 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 2 | 2015 | 98 | 0.140 |
Why?
| | Multivariate Analysis | 3 | 2019 | 1430 | 0.140 |
Why?
| | Cell Division | 2 | 1997 | 758 | 0.140 |
Why?
| | Immunity, Cellular | 1 | 2019 | 248 | 0.140 |
Why?
| | Postoperative Care | 2 | 2017 | 222 | 0.140 |
Why?
| | Radiobiology | 3 | 2008 | 4 | 0.140 |
Why?
| | Health Planning | 1 | 2017 | 46 | 0.140 |
Why?
| | Maximum Tolerated Dose | 4 | 2010 | 183 | 0.140 |
Why?
| | Thymus Neoplasms | 1 | 2017 | 21 | 0.140 |
Why?
| | Thymoma | 1 | 2017 | 30 | 0.140 |
Why?
| | Perioperative Care | 1 | 2018 | 127 | 0.140 |
Why?
| | Cause of Death | 2 | 2017 | 361 | 0.140 |
Why?
| | Disease Progression | 7 | 2019 | 2380 | 0.140 |
Why?
| | Consensus Development Conferences, NIH as Topic | 1 | 2016 | 2 | 0.140 |
Why?
| | Preoperative Period | 1 | 2017 | 103 | 0.130 |
Why?
| | Flunarizine | 2 | 1993 | 2 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 193 | 0.130 |
Why?
| | Monitoring, Intraoperative | 1 | 2016 | 38 | 0.130 |
Why?
| | Health Expenditures | 1 | 2017 | 171 | 0.130 |
Why?
| | Pulmonary Atelectasis | 1 | 2015 | 11 | 0.130 |
Why?
| | Glioma | 2 | 2010 | 294 | 0.130 |
Why?
| | Precision Medicine | 2 | 2017 | 336 | 0.130 |
Why?
| | Gastrointestinal Tract | 1 | 2018 | 169 | 0.130 |
Why?
| | Oximetry | 1 | 2016 | 81 | 0.130 |
Why?
| | Salvage Therapy | 4 | 2017 | 127 | 0.120 |
Why?
| | Clinical Competence | 2 | 2022 | 893 | 0.120 |
Why?
| | Neurosurgery | 1 | 2015 | 26 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 668 | 0.120 |
Why?
| | Multimodal Imaging | 2 | 2013 | 88 | 0.120 |
Why?
| | Intensive Care Units | 1 | 1999 | 617 | 0.120 |
Why?
| | Induction Chemotherapy | 2 | 2013 | 56 | 0.120 |
Why?
| | Drug Administration Schedule | 3 | 2014 | 718 | 0.120 |
Why?
| | Vaginal Neoplasms | 1 | 1994 | 11 | 0.120 |
Why?
| | Sensitivity and Specificity | 5 | 2016 | 1691 | 0.120 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 90 | 0.120 |
Why?
| | Perineum | 1 | 1994 | 25 | 0.120 |
Why?
| | Health Services Research | 1 | 2017 | 371 | 0.120 |
Why?
| | Quality Control | 5 | 2013 | 144 | 0.120 |
Why?
| | Marital Status | 1 | 2014 | 41 | 0.120 |
Why?
| | Incidence | 3 | 2016 | 2311 | 0.120 |
Why?
| | Maytansine | 1 | 2014 | 13 | 0.120 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2014 | 9 | 0.120 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2014 | 7 | 0.120 |
Why?
| | Nuclear Medicine | 1 | 2014 | 7 | 0.120 |
Why?
| | Prostate | 1 | 2015 | 156 | 0.120 |
Why?
| | Risk | 3 | 2016 | 812 | 0.120 |
Why?
| | Takayasu Arteritis | 1 | 1994 | 8 | 0.110 |
Why?
| | Brain Edema | 1 | 2014 | 60 | 0.110 |
Why?
| | Cerebrovascular Circulation | 1 | 2016 | 221 | 0.110 |
Why?
| | Radiotherapy Setup Errors | 1 | 2013 | 3 | 0.110 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 16 | 0.110 |
Why?
| | Health Status Disparities | 1 | 2016 | 200 | 0.110 |
Why?
| | Cell Survival | 3 | 2008 | 1020 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1141 | 0.110 |
Why?
| | Piperidines | 2 | 2015 | 160 | 0.110 |
Why?
| | Oropharyngeal Neoplasms | 1 | 1994 | 38 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1214 | 0.110 |
Why?
| | Xerostomia | 1 | 1993 | 19 | 0.110 |
Why?
| | Erythrocytes | 2 | 2001 | 591 | 0.110 |
Why?
| | Blood Viscosity | 1 | 1993 | 16 | 0.110 |
Why?
| | Observer Variation | 1 | 2014 | 295 | 0.110 |
Why?
| | Health Care Reform | 1 | 2014 | 92 | 0.110 |
Why?
| | Calcium | 2 | 1998 | 1104 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2015 | 268 | 0.110 |
Why?
| | Lactates | 1 | 1993 | 79 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2018 | 479 | 0.100 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 328 | 0.100 |
Why?
| | Physicians | 1 | 2020 | 772 | 0.100 |
Why?
| | Age Factors | 2 | 2021 | 2894 | 0.100 |
Why?
| | Radiology | 1 | 2014 | 141 | 0.100 |
Why?
| | Motion | 2 | 2011 | 90 | 0.100 |
Why?
| | Partial Pressure | 2 | 2002 | 30 | 0.100 |
Why?
| | Colorado | 5 | 2015 | 4099 | 0.100 |
Why?
| | Biomedical Research | 1 | 2017 | 585 | 0.100 |
Why?
| | Organ Specificity | 2 | 2021 | 268 | 0.100 |
Why?
| | Oxytocin | 1 | 1992 | 45 | 0.100 |
Why?
| | Cardiac Surgical Procedures | 1 | 2016 | 414 | 0.100 |
Why?
| | Hepatic Veins | 1 | 2011 | 29 | 0.100 |
Why?
| | Remission Induction | 3 | 2008 | 233 | 0.090 |
Why?
| | Eponyms | 1 | 1991 | 1 | 0.090 |
Why?
| | Esophageal Neoplasms | 2 | 2008 | 273 | 0.090 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2009 | 98 | 0.090 |
Why?
| | Esophagectomy | 1 | 1992 | 111 | 0.090 |
Why?
| | Delphi Technique | 2 | 2022 | 160 | 0.090 |
Why?
| | Computer Simulation | 3 | 2012 | 872 | 0.090 |
Why?
| | Young Adult | 9 | 2018 | 10455 | 0.090 |
Why?
| | Burkitt Lymphoma | 1 | 1991 | 52 | 0.090 |
Why?
| | Keratin-18 | 1 | 2010 | 10 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4620 | 0.090 |
Why?
| | Automation | 2 | 2020 | 73 | 0.090 |
Why?
| | Neoplasm, Residual | 1 | 2010 | 104 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 663 | 0.090 |
Why?
| | Meningeal Neoplasms | 2 | 2021 | 87 | 0.080 |
Why?
| | Respiration | 2 | 2023 | 179 | 0.080 |
Why?
| | History, 20th Century | 2 | 2006 | 264 | 0.080 |
Why?
| | Radiation Dosage | 3 | 2019 | 132 | 0.080 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2010 | 52 | 0.080 |
Why?
| | Catheter Ablation | 1 | 2012 | 288 | 0.080 |
Why?
| | Immobilization | 2 | 2010 | 42 | 0.080 |
Why?
| | Risk Management | 2 | 2020 | 89 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 235 | 0.080 |
Why?
| | Sex Factors | 1 | 2014 | 1715 | 0.080 |
Why?
| | Anthracyclines | 1 | 2009 | 41 | 0.080 |
Why?
| | Thoracic Wall | 1 | 2009 | 14 | 0.080 |
Why?
| | Rib Fractures | 1 | 2009 | 25 | 0.080 |
Why?
| | Neuroblastoma | 1 | 2010 | 133 | 0.080 |
Why?
| | Feasibility Studies | 4 | 2016 | 739 | 0.080 |
Why?
| | Chest Pain | 1 | 2009 | 81 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2009 | 687 | 0.080 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2009 | 109 | 0.080 |
Why?
| | Cross-Priming | 1 | 2008 | 18 | 0.080 |
Why?
| | Lymphocyte Count | 1 | 2008 | 133 | 0.080 |
Why?
| | Pharyngeal Neoplasms | 1 | 2007 | 3 | 0.080 |
Why?
| | Carcinoembryonic Antigen | 1 | 2008 | 37 | 0.080 |
Why?
| | Treatment Failure | 4 | 2014 | 331 | 0.070 |
Why?
| | Bile Duct Diseases | 1 | 2008 | 15 | 0.070 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2008 | 17 | 0.070 |
Why?
| | Ki-67 Antigen | 1 | 2008 | 103 | 0.070 |
Why?
| | Statistics, Nonparametric | 2 | 2018 | 385 | 0.070 |
Why?
| | Malaria Vaccines | 1 | 2007 | 6 | 0.070 |
Why?
| | Pancreatic Neoplasms | 1 | 2014 | 731 | 0.070 |
Why?
| | Software | 1 | 2012 | 529 | 0.070 |
Why?
| | Hemocyanins | 1 | 2007 | 55 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2010 | 2710 | 0.070 |
Why?
| | Laryngeal Neoplasms | 1 | 2007 | 27 | 0.070 |
Why?
| | Photons | 1 | 2008 | 56 | 0.070 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2008 | 48 | 0.070 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2008 | 39 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 913 | 0.070 |
Why?
| | Fluorouracil | 1 | 2008 | 152 | 0.070 |
Why?
| | Deoxycytidine | 1 | 2008 | 138 | 0.070 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2008 | 154 | 0.070 |
Why?
| | Mouth Neoplasms | 1 | 2007 | 70 | 0.070 |
Why?
| | Accreditation | 2 | 2022 | 76 | 0.070 |
Why?
| | DNA Repair | 1 | 2008 | 184 | 0.070 |
Why?
| | Antigen Presentation | 1 | 2007 | 188 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 311 | 0.070 |
Why?
| | Urinary Tract | 1 | 2006 | 36 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 309 | 0.070 |
Why?
| | Reproducibility of Results | 4 | 2016 | 2762 | 0.070 |
Why?
| | Postoperative Nausea and Vomiting | 1 | 2006 | 10 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2007 | 206 | 0.070 |
Why?
| | Oligopeptides | 1 | 2008 | 236 | 0.070 |
Why?
| | Hodgkin Disease | 1 | 2008 | 120 | 0.070 |
Why?
| | Whole Body Imaging | 1 | 2006 | 19 | 0.070 |
Why?
| | Cisplatin | 2 | 2011 | 262 | 0.060 |
Why?
| | DNA Damage | 1 | 2008 | 351 | 0.060 |
Why?
| | Vertigo | 1 | 2006 | 37 | 0.060 |
Why?
| | Intestines | 1 | 2009 | 326 | 0.060 |
Why?
| | Cranial Nerve Diseases | 1 | 2006 | 42 | 0.060 |
Why?
| | Heart Diseases | 1 | 2009 | 331 | 0.060 |
Why?
| | Physics | 4 | 2010 | 17 | 0.060 |
Why?
| | History, 21st Century | 1 | 2006 | 159 | 0.060 |
Why?
| | Heart | 2 | 2020 | 612 | 0.060 |
Why?
| | Kidney | 2 | 2010 | 1188 | 0.060 |
Why?
| | Light | 1 | 2008 | 336 | 0.060 |
Why?
| | Immunotherapy | 1 | 2009 | 474 | 0.060 |
Why?
| | Brain | 3 | 2022 | 2371 | 0.060 |
Why?
| | Medical Records | 3 | 2010 | 153 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2010 | 2186 | 0.060 |
Why?
| | Receptor, ErbB-2 | 2 | 2019 | 300 | 0.060 |
Why?
| | Pilot Projects | 2 | 2001 | 1372 | 0.060 |
Why?
| | Adolescent | 6 | 2018 | 17831 | 0.060 |
Why?
| | Bevacizumab | 2 | 2015 | 115 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2007 | 719 | 0.060 |
Why?
| | Body Burden | 1 | 2003 | 5 | 0.060 |
Why?
| | Cell Count | 2 | 1995 | 303 | 0.060 |
Why?
| | Maximum Allowable Concentration | 1 | 2003 | 14 | 0.060 |
Why?
| | Costs and Cost Analysis | 2 | 2001 | 195 | 0.060 |
Why?
| | Abdomen | 1 | 2023 | 99 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 238 | 0.050 |
Why?
| | Forecasting | 2 | 2017 | 330 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 1262 | 0.050 |
Why?
| | Vasopressins | 2 | 1993 | 56 | 0.050 |
Why?
| | Peptides | 1 | 2007 | 848 | 0.050 |
Why?
| | Research Design | 2 | 2018 | 928 | 0.050 |
Why?
| | Certification | 2 | 2015 | 89 | 0.050 |
Why?
| | Electrodes | 1 | 2022 | 100 | 0.050 |
Why?
| | Comorbidity | 2 | 2017 | 1448 | 0.050 |
Why?
| | Pulmonary Gas Exchange | 1 | 2002 | 117 | 0.050 |
Why?
| | Parotid Gland | 1 | 2001 | 24 | 0.050 |
Why?
| | Mastectomy | 1 | 2022 | 99 | 0.050 |
Why?
| | Oxygen Consumption | 2 | 2016 | 588 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-raf | 2 | 1998 | 43 | 0.050 |
Why?
| | Apoptosis | 1 | 2010 | 2362 | 0.050 |
Why?
| | Rats | 3 | 2002 | 4958 | 0.050 |
Why?
| | Hepatitis B | 1 | 2001 | 51 | 0.050 |
Why?
| | Carboplatin | 2 | 2011 | 135 | 0.050 |
Why?
| | Probability | 1 | 2001 | 289 | 0.040 |
Why?
| | Skull Neoplasms | 1 | 2000 | 22 | 0.040 |
Why?
| | Camptothecin | 2 | 2011 | 96 | 0.040 |
Why?
| | Alveolar Process | 1 | 2000 | 6 | 0.040 |
Why?
| | Maxilla | 1 | 2000 | 29 | 0.040 |
Why?
| | Patient Positioning | 1 | 2020 | 42 | 0.040 |
Why?
| | Hospitals, Community | 1 | 2000 | 45 | 0.040 |
Why?
| | Palate | 1 | 2000 | 28 | 0.040 |
Why?
| | Canada | 1 | 2021 | 322 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 2000 | 79 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2008 | 1177 | 0.040 |
Why?
| | Meningioma | 1 | 2000 | 77 | 0.040 |
Why?
| | Enzyme Activation | 2 | 1998 | 785 | 0.040 |
Why?
| | Ontario | 1 | 1999 | 74 | 0.040 |
Why?
| | APACHE | 1 | 1999 | 58 | 0.040 |
Why?
| | Health Care Rationing | 1 | 1999 | 45 | 0.040 |
Why?
| | Dexamethasone | 2 | 2012 | 317 | 0.040 |
Why?
| | Europe | 1 | 2020 | 334 | 0.040 |
Why?
| | Workflow | 1 | 2020 | 133 | 0.040 |
Why?
| | Lymphopenia | 1 | 2019 | 49 | 0.040 |
Why?
| | Fibrosarcoma | 1 | 1999 | 20 | 0.040 |
Why?
| | Reoperation | 2 | 2012 | 514 | 0.040 |
Why?
| | Hepatitis C | 1 | 2001 | 219 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2019 | 293 | 0.040 |
Why?
| | Neutropenia | 1 | 2019 | 125 | 0.040 |
Why?
| | Egtazic Acid | 1 | 1998 | 44 | 0.040 |
Why?
| | Safety | 1 | 2000 | 297 | 0.040 |
Why?
| | Cell Line | 2 | 2008 | 2635 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 368 | 0.040 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1998 | 153 | 0.040 |
Why?
| | Triage | 1 | 2020 | 199 | 0.040 |
Why?
| | Immune System | 1 | 2019 | 172 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1998 | 284 | 0.040 |
Why?
| | Tyrphostins | 1 | 1997 | 13 | 0.040 |
Why?
| | Neurosurgeons | 1 | 2017 | 13 | 0.040 |
Why?
| | Patient Admission | 1 | 1999 | 176 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2000 | 410 | 0.040 |
Why?
| | Headache | 1 | 1998 | 132 | 0.040 |
Why?
| | Tumor Cells, Cultured | 2 | 1997 | 849 | 0.040 |
Why?
| | Lymphocytes | 1 | 2019 | 330 | 0.040 |
Why?
| | Medicaid | 1 | 2021 | 406 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 1999 | 218 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 250 | 0.030 |
Why?
| | Curriculum | 1 | 2022 | 819 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 822 | 0.030 |
Why?
| | Syndrome | 2 | 2008 | 333 | 0.030 |
Why?
| | Protein Kinase C | 1 | 1998 | 273 | 0.030 |
Why?
| | Movement | 2 | 2010 | 244 | 0.030 |
Why?
| | Biopsy | 1 | 2000 | 1036 | 0.030 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 152 | 0.030 |
Why?
| | Contrast Media | 1 | 1998 | 345 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 106 | 0.030 |
Why?
| | Abdominal Neoplasms | 1 | 2015 | 26 | 0.030 |
Why?
| | Rats, Inbred F344 | 2 | 1993 | 241 | 0.030 |
Why?
| | Causality | 1 | 2016 | 103 | 0.030 |
Why?
| | Mutation | 2 | 2019 | 3344 | 0.030 |
Why?
| | Seizures | 1 | 1998 | 340 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2006 | 2128 | 0.030 |
Why?
| | Ions | 1 | 2015 | 59 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2016 | 121 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 138 | 0.030 |
Why?
| | Carbazoles | 1 | 2015 | 78 | 0.030 |
Why?
| | Age Distribution | 1 | 2016 | 342 | 0.030 |
Why?
| | Patient Education as Topic | 2 | 2010 | 680 | 0.030 |
Why?
| | Communication | 1 | 2020 | 744 | 0.030 |
Why?
| | Sulfones | 1 | 2015 | 97 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 913 | 0.030 |
Why?
| | Length of Stay | 1 | 1999 | 962 | 0.030 |
Why?
| | Doxorubicin | 2 | 2008 | 285 | 0.030 |
Why?
| | Netherlands | 1 | 2014 | 64 | 0.030 |
Why?
| | Vital Capacity | 1 | 2015 | 255 | 0.030 |
Why?
| | North Carolina | 1 | 2014 | 97 | 0.030 |
Why?
| | Sigmoid Neoplasms | 1 | 1994 | 3 | 0.030 |
Why?
| | Critical Illness | 1 | 1999 | 644 | 0.030 |
Why?
| | Texas | 1 | 2014 | 188 | 0.030 |
Why?
| | Trastuzumab | 1 | 2014 | 89 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2018 | 515 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 599 | 0.030 |
Why?
| | Neutrophils | 1 | 2019 | 1176 | 0.030 |
Why?
| | Spatial Analysis | 1 | 2013 | 20 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 475 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1077 | 0.030 |
Why?
| | Erythrocyte Deformability | 1 | 1993 | 12 | 0.030 |
Why?
| | Choice Behavior | 1 | 2014 | 155 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2013 | 138 | 0.030 |
Why?
| | Cell Cycle | 1 | 1995 | 542 | 0.030 |
Why?
| | Animals | 5 | 2010 | 31695 | 0.030 |
Why?
| | Medical Errors | 1 | 2013 | 85 | 0.030 |
Why?
| | Rheology | 1 | 1993 | 86 | 0.030 |
Why?
| | Regression Analysis | 1 | 2015 | 944 | 0.030 |
Why?
| | Fiducial Markers | 1 | 2012 | 8 | 0.030 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 1992 | 64 | 0.030 |
Why?
| | Neurophysins | 1 | 1992 | 5 | 0.030 |
Why?
| | Arginine Vasopressin | 1 | 1992 | 46 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1992 | 187 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1993 | 511 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2387 | 0.020 |
Why?
| | Genomics | 1 | 2016 | 635 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 1992 | 157 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1342 | 0.020 |
Why?
| | Lactic Acid | 1 | 1993 | 275 | 0.020 |
Why?
| | Protein Precursors | 1 | 1992 | 119 | 0.020 |
Why?
| | Etoposide | 1 | 2011 | 148 | 0.020 |
Why?
| | Patient Participation | 1 | 2014 | 359 | 0.020 |
Why?
| | Fibrosis | 1 | 2013 | 453 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3003 | 0.020 |
Why?
| | Africa | 1 | 1991 | 94 | 0.020 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 12 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 67 | 0.020 |
Why?
| | Amino Acid Chloromethyl Ketones | 1 | 2010 | 23 | 0.020 |
Why?
| | United Kingdom | 1 | 1991 | 226 | 0.020 |
Why?
| | Carmustine | 1 | 2010 | 47 | 0.020 |
Why?
| | Paclitaxel | 1 | 2011 | 190 | 0.020 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2010 | 45 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 98 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 119 | 0.020 |
Why?
| | Palliative Care | 2 | 2012 | 642 | 0.020 |
Why?
| | Caspase Inhibitors | 1 | 2010 | 78 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 283 | 0.020 |
Why?
| | Physical Phenomena | 2 | 1999 | 12 | 0.020 |
Why?
| | Kinetics | 1 | 1993 | 1551 | 0.020 |
Why?
| | Lymphatic Irradiation | 1 | 2009 | 9 | 0.020 |
Why?
| | Urination Disorders | 1 | 2009 | 11 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 1840 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 1997 | 2537 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 213 | 0.020 |
Why?
| | Cystitis | 1 | 2009 | 20 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 927 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 11 | 0.020 |
Why?
| | Ipilimumab | 1 | 2009 | 27 | 0.020 |
Why?
| | Nephrectomy | 1 | 2010 | 150 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 137 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 447 | 0.020 |
Why?
| | RNA Interference | 1 | 2010 | 433 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 36 | 0.020 |
Why?
| | Smoking | 1 | 2015 | 1380 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 728 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
| | Models, Animal | 1 | 2010 | 344 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 797 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 81 | 0.020 |
Why?
| | Hemodynamics | 1 | 1992 | 1012 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 33 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2008 | 217 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1147 | 0.020 |
Why?
| | Forearm | 1 | 2008 | 112 | 0.020 |
Why?
| | HIV Infections | 1 | 2001 | 2469 | 0.020 |
Why?
| | Prednisone | 1 | 2008 | 229 | 0.020 |
Why?
| | Diarrhea | 1 | 2008 | 171 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2007 | 59 | 0.020 |
Why?
| | Pain Measurement | 1 | 2009 | 444 | 0.020 |
Why?
| | Medical History Taking | 1 | 2007 | 114 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2010 | 445 | 0.020 |
Why?
| | Tomography, Spiral Computed | 1 | 2006 | 23 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 532 | 0.020 |
Why?
| | Cognition | 1 | 2013 | 988 | 0.020 |
Why?
| | Pedigree | 1 | 2007 | 460 | 0.020 |
Why?
| | Epitopes | 1 | 2008 | 435 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2010 | 490 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1993 | 3881 | 0.020 |
Why?
| | Antiemetics | 1 | 2005 | 32 | 0.020 |
Why?
| | Spinal Cord Neoplasms | 1 | 2004 | 37 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 1982 | 0.010 |
Why?
| | Testosterone | 1 | 2007 | 343 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1993 | 3531 | 0.010 |
Why?
| | Esthetics | 1 | 2003 | 37 | 0.010 |
Why?
| | Mastectomy, Segmental | 1 | 2003 | 76 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2785 | 0.010 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2003 | 49 | 0.010 |
Why?
| | Carcinoma, Lobular | 1 | 2003 | 44 | 0.010 |
Why?
| | Spinal Cord | 1 | 2005 | 347 | 0.010 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2003 | 76 | 0.010 |
Why?
| | Signal Transduction | 2 | 2010 | 4509 | 0.010 |
Why?
| | Craniotomy | 1 | 2000 | 68 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2000 | 176 | 0.010 |
Why?
| | Iridium Radioisotopes | 1 | 1999 | 5 | 0.010 |
Why?
| | Skull | 1 | 2000 | 119 | 0.010 |
Why?
| | Antisickling Agents | 1 | 1999 | 5 | 0.010 |
Why?
| | Cobalt Radioisotopes | 1 | 1999 | 6 | 0.010 |
Why?
| | Surgical Flaps | 1 | 2000 | 121 | 0.010 |
Why?
| | Tumor Stem Cell Assay | 1 | 1999 | 33 | 0.010 |
Why?
| | Oxyhemoglobins | 1 | 1999 | 20 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 2000 | 442 | 0.010 |
Why?
| | Allosteric Regulation | 1 | 1999 | 81 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1999 | 239 | 0.010 |
Why?
| | Phosphotyrosine | 1 | 1997 | 33 | 0.010 |
Why?
| | Inositol 1,4,5-Trisphosphate | 1 | 1997 | 27 | 0.010 |
Why?
| | Phospholipase C gamma | 1 | 1997 | 26 | 0.010 |
Why?
| | Type C Phospholipases | 1 | 1997 | 65 | 0.010 |
Why?
| | Radiation, Ionizing | 1 | 1997 | 72 | 0.010 |
Why?
| | Nitriles | 1 | 1997 | 149 | 0.010 |
Why?
| | Pulmonary Circulation | 1 | 1999 | 407 | 0.010 |
Why?
| | Hemoglobins | 1 | 1999 | 315 | 0.010 |
Why?
| | Isoenzymes | 1 | 1997 | 283 | 0.010 |
Why?
| | Bronchial Neoplasms | 1 | 1995 | 14 | 0.010 |
Why?
| | Child | 2 | 2008 | 18404 | 0.010 |
Why?
| | Child, Preschool | 1 | 2008 | 9108 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 1997 | 750 | 0.010 |
Why?
| | Endometrial Neoplasms | 1 | 1995 | 141 | 0.010 |
Why?
| | Postoperative Period | 1 | 1994 | 289 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1992 | 228 | 0.010 |
Why?
| | Microcirculation | 1 | 1992 | 135 | 0.010 |
Why?
| | Mice | 1 | 1999 | 14860 | 0.000 |
Why?
|
|
Kavanagh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|